Lissoni P, Barni S, Crispino S, Cattaneo G, Tancini G
Division of Radiation Oncology, Ospedale San Gerardo, Monza, Italy.
Tumori. 1988 Jun 30;74(3):303-8. doi: 10.1177/030089168807400310.
Buserelin represents one of the main LHRH analogues. It appears to be effective in untreated metastatic breast cancer, whereas its activity in pretreated advanced patients remains to be established. To evaluate endocrine and clinical effects of buserelin in pretreated advanced mammary carcinoma, 14 postmenopausal women with metastatic breast cancer, which had been previously treated with hormones and/or chemotherapy, entered the study. Buserelin was subcutaneously injected at a daily dose of 1.5 mg for 7 days, then intranasally at a daily dose of 1.2 mg until progression. Before and after the 7 days of subcutaneous administration of the LHRH analogue, FSH, LH, estradiol, testosterone basal serum levels, and PRL response to TRH were examined. After the 7 days of buserelin subcutaneous injection, a significant decrease in FSH, LH and estradiol values was observed, whereas testosterone was not affected. PRL response to TRH did not change after buserelin subcutaneous treatment in 8 patients, it decreased in one and was completely abolished in the last 5 cases. All patients whose PRL response to TRH did not decrease had a progression within the first month of therapy, whereas only 1 of 6 patients whose PRL response to TRH was reduced or abolished following buserelin administration showed a progression. Among the other 5 cases, 2 minor responses and 3 stable diseases were achieved. These preliminary results suggest that buserelin has only a limited effectiveness in metastatic breast cancer patients who have been previously treated with hormones and/or chemotherapy, and that its activity in the control of tumor growth is associated with a reduction in PRL secretion.
布舍瑞林是主要的促黄体生成素释放激素（LHRH）类似物之一。它在未经治疗的转移性乳腺癌中似乎有效，而其在先前接受过治疗的晚期患者中的活性仍有待确定。为了评估布舍瑞林在先前接受过治疗的晚期乳腺癌中的内分泌和临床效果，14名绝经后转移性乳腺癌妇女进入了该研究，这些患者先前已接受过激素和/或化疗。布舍瑞林皮下注射，每日剂量为1.5毫克，共7天，然后鼻内给药，每日剂量为1.2毫克，直至病情进展。在促黄体生成素释放激素类似物皮下给药7天前后，检测了促卵泡生成素（FSH）、促黄体生成素（LH）、雌二醇、睾酮的基础血清水平以及催乳素（PRL）对促甲状腺激素释放激素（TRH）的反应。布舍瑞林皮下注射7天后，观察到FSH、LH和雌二醇值显著下降，而睾酮未受影响。8名患者在布舍瑞林皮下治疗后，PRL对TRH的反应没有变化，1名患者反应下降，最后5名患者反应完全消失。所有PRL对TRH反应未降低的患者在治疗的第一个月内病情进展，而在布舍瑞林给药后PRL对TRH反应降低或消失的6名患者中，只有1名出现病情进展。在其他5例患者中，2例有轻微反应，3例病情稳定。这些初步结果表明，布舍瑞林在先前接受过激素和/或化疗的转移性乳腺癌患者中疗效有限，其控制肿瘤生长的活性与PRL分泌减少有关。
